Search Results

Introduction Most blood donors walk out of the collection center with little more than a bandage and a juice box. But for a small subset, the donation experience can be complicated by physiologic reactions—ranging from mild lightheadedness to full-blown syncope. These events, often referred to as “donor reactions,” are typically benign and self-limited, but they matter. For transfusion medicine physicians and trainees, recognizing and managing these reactions is critical—not just for donor safety, but for maintaining public trust in the blood supply. This post outlines the most common donor reactions, their mechanisms, risk factors, and management strategies, with a focus on practical relevance for pathology residents and fellows rotating through transfusion medicine. What Is a Donor Reaction? A donor reaction refers to any adverse response experienced by a blood donor during or shortly after donation. While most are mild, some can be alarming or—rarely—require clinical intervention. Reactions are classified by physiologic mechanism (e.g., vasovagal, mechanical, or citrate-related) and by severity (mild, moderate, or severe). Understanding how to identify, manage, and prevent these events is essential for ensuring a safe and positive donation experience. The Most Common Reactions Vasovagal Reactions These are the most common donor reactions and are caused by increased vagal tone, leading to transient hypotension and bradycardia. Clinical features include: Lightheadedness, dizziness, visual changes Nausea Sweating, pallor Syncope—with or without convulsions , which can be brief and non-epileptic but very alarming Management: Prompt recognition of prodrome Supine positioning with legs elevated Cold compresses to face and neck Reassurance and quiet environment Monitor until symptoms resolve Syncope is more common in: First-time donors Younger donors (particularly adolescents) Female donors , likely due to a combination of physiologic and psychosocial factors Donors with low blood volume or anxiety Hematoma Formation and Bruising Occurs when blood leaks from the vein into surrounding tissue, often from a partial needle dislodgement or inadequate compression post-donation. Management: Immediate removal of needle if infiltration occurs Apply firm pressure until bleeding stops Cold compresses in the first 24 hours; warm compresses afterward Pressure dressing  for larger hematomas Documentation and follow-up if significant Citrate Reaction (Apheresis Only) Due to systemic binding of ionized calcium by citrate anticoagulant: Perioral or fingertip tingling Muscle cramping Nausea Metallic taste Rarely, severe symptoms like tetany or arrhythmias Management: Oral calcium supplementation Slowing the ACD infusion rate Intravenous calcium in rare severe cases Nausea and Vomiting May overlap with vasovagal symptoms or occur due to anxiety, dehydration, or prolonged fasting. Management: Supine positioning Fluids and rest Discreet handling and privacy for emesis events Delayed Reactions Some donors feel dizzy or fatigued hours later, especially if they resume vigorous activity too soon. Management: Education at time of donation: hydration, rest, activity restrictions Provide emergency contact if symptoms worsen Less Common but Important Reactions Nerve Irritation or Injury Direct trauma or compression of adjacent nerves (e.g., median or cutaneous nerves) may result in: Shooting or radiating pain during phlebotomy Persistent numbness, tingling, or weakness Management: Immediate needle removal if pain occurs Documentation and donor follow-up Referral to occupational health if symptoms persist Arterial Puncture Rare but potentially serious complication when an artery is inadvertently accessed instead of a vein. Signs: Rapid filling of collection bag Bright red, pulsatile blood High pressure flow into the tubing Hematoma formation at site Management: Immediate cessation of collection Remove needle and apply firm, prolonged pressure  (at least 10 minutes) Use a pressure dressing Document and advise donor to seek care for signs of compartment syndrome or neurologic deficits Who's at Risk? Certain donor profiles consistently show higher rates of adverse reactions. First-time donors  are especially vulnerable due to unfamiliarity, needle anxiety, or fear of the process. Adolescents and young adults —particularly female donors —also experience higher rates of vasovagal syncope, likely due to heightened autonomic reactivity and lower circulating blood volume. Add dehydration, low BMI, or a skipped meal, and the risk rises further. A quick pre-donation conversation can go a long way: asking about prior reactions, encouraging hydration, and recognizing nervous body language are simple, high-yield interventions for anticipating and reducing reactions. Prevention and Mitigation Strategies Donor safety starts before the needle is even placed. Encourage donors to hydrate and eat beforehand, and offer a salty snack to expand plasma volume. For apheresis donors, provide oral calcium to prevent citrate-related symptoms. During collection, reclined positioning and attentive monitoring are key. Early signs of a vasovagal reaction—yawning, pallor, sweating—should prompt immediate action: stop the draw, recline the donor, apply cold compresses, and offer reassurance. Most syncopal episodes resolve quickly with these measures. Post-donation, ensure donors rest briefly, hydrate, and receive clear instructions about avoiding strenuous activity. Empathetic handling of reactions reinforces trust and can turn even a rocky first donation into a repeat experience. Why It Matters Donor reactions are not just operational issues—they are clinical events that influence public trust in the blood supply. Even minor reactions can deter repeat donation. As pathology residents and fellows, you may be called on to evaluate donor events, participate in root cause analysis, or improve donor screening and safety protocols. Your ability to understand and address these events directly impacts donor retention and transfusion system integrity. Final Thoughts Common donor reactions are rarely dangerous but deserve careful attention. Early recognition, effective management, and thorough documentation help keep donors safe and confident in the system. From a minor faint to a hematoma to a rare arterial puncture, every reaction is an opportunity to improve our systems—and to advocate for those whose generosity makes transfusion possible.

Warm autoantibodies (WAAs) are one of the most conceptually strange and serologically compelling phenomena in transfusion medicine. They break all the rules. And a recent case reminded me just how much art is involved in managing them—even when the science is sound. The patient was an older adult with newly identified anemia. The indirect antiglobulin test (IAT) was strongly panreactive at 4+. The direct antiglobulin test (DAT) lit up too—4+ with polyspecific antihuman globulin and anti-IgG, but negative with anti-C3. There were signs of hemolysis: elevated LDH and indirect bilirubin, downtrending haptoglobin. But the serum remained visually clear—no hemoglobinemia. Just a steady, smoldering hemolytic process consistent with warm autoimmune hemolytic anemia (WAIHA). Warm autoantibodies, as a reminder, are IgG antibodies directed against “self” antigens on red blood cells. They react best at 37°C—hence the name—and often appear as panagglutinins, reacting with all red cells regardless of antigen profile. While their specificity is typically undefined, they occasionally show preferential reactivity against Rh system antigens, especially RhD. But more often than not, the pattern is messy and nonspecific. What’s fascinating is that despite this overwhelming in vitro reactivity, patients with WAAs— even those with active hemolysis like mine —can often tolerate allogeneic transfusion just fine. That paradox is what makes WAAs so serologically intriguing and clinically humbling. The Practical Challenges of WAAs Rule Out Alloantibodies & Choose the Right Blood: The first priority is identifying any additional  alloantibodies that might be hiding beneath the autoantibody. This can require special techniques like autoadsorption or “saline AHG” testing that dampen WAA reactivity while preserving alloantibody detection. Once that’s done, most institutions provide ABO- and Rh-compatible units and match for Rh and Kell antigens the patient lacks to reduce future alloimmunization. There’s no universal standard for how far to take matching, but Rh/Kell coverage is a common and practical middle ground. Overlook the Incompatible Crossmatch—Sort Of: After all that, the crossmatch will almost always remain incompatible. And that’s okay. The phrase “least incompatible unit” gets tossed around a lot, but it’s not a guarantee of safety—just a shorthand for “we did our due diligence.” In truth, no serologic grading system has been validated to predict transfusion success in WAA cases. The unit that gives a 1+ reaction doesn’t necessarily survive better than one that’s 3+. What matters is clinical judgment and communication. Communicate Clearly with Clinicians: A DAT-positive patient, a fully incompatible crossmatch, and ongoing hemolysis can sound like a disaster to non-hematology clinicians. It’s our job to demystify that. I find myself saying this often: Yes, it looks scary on paper. But we’ve ruled out alloantibodies, chosen appropriate antigen-negative blood, and transfusion is still safe and appropriate when clinically indicated.  Avoid empty reassurances. Focus on shared decision-making. A Clinical Balancing Act WAAs can drive clinically significant hemolysis of the patient’s own red cells, and on occasion transfused donor cells. But not always, and paradoxically WAAs can sometimes spare donor cells while destroying native cells. That variability is part of what makes these antibodies so clinically fascinating. In vitro, they react with everything. In vivo, their effects exist on a spectrum—from silent bystanders to active participants in hemolysis. Managing WAAs is a constant balancing act. It requires knowing when to move forward despite serologic incompatibility, and when to stop and reassess. It demands vigilance, nuance, and collaboration. These antibodies force us to think beyond the test tube and remember that in transfusion medicine, the right answer is rarely just a result—it’s a decision.

When a patient refuses a blood transfusion, many clinicians feel backed into a corner. Sometimes, that refusal stems from deeply held religious beliefs—most notably among Jehovah’s Witnesses, who typically decline whole blood and its primary components. But here's the truth: refusing transfusion doesn’t mean refusing care. It means we need to be better stewards of everything else we have. 🔄 From “No” to “Now What?” Too often, the conversation stops at “They won’t accept blood.” But clinically, the more urgent question is: what can we offer instead? Fortunately, there’s a growing arsenal of strategies—many pioneered in response to transfusion refusal—that improve outcomes across the board. And the data backs that up. 💉 Bloodless Cardiac Surgery: The Data Consider cardiac surgery, one of the most transfusion-intensive fields in modern medicine. In a 10-year retrospective study of 91 Jehovah’s Witness patients undergoing cardiac procedures at a single institution, in-hospital mortality was just 5.5%, with outcomes for isolated coronary artery bypass grafting (CABG) and aortic valve replacement (AVR) falling within the 95% confidence intervals of Society of Thoracic Surgeons (STS) risk model predictions. Major complications—including reoperation, sepsis, stroke, and dialysis—remained low, and results were consistent across both elective and urgent surgeries.¹ These findings are echoed in a 2024 meta-analysis of 10 studies involving 780 Jehovah’s Witnesses and 1,182 non-Witness controls undergoing cardiac surgery. Despite 86% of non-Witness patients receiving at least one transfusion, there was no significant difference in perioperative mortality (OR 0.91; 95% CI, 0.55–1.52; p = 0.72). Jehovah’s Witnesses had less total blood loss (p = 0.001), and both pre- and postoperative hemoglobin levels were significantly higher.² In short: bloodless cardiac surgery is not only possible—it’s safe, when care is proactive and deliberate. 🧬 Blood Products and the Nuance of Refusal To care well for patients who decline transfusion, we need more than clinical tools—we need clarity. Here's the breakdown: Whole Blood Contains all components: red cells, white cells, plasma, and platelets. Jehovah’s Witnesses universally reject transfusion of whole blood. Primary Components Directly separated from whole blood. These are typically not accepted. Red blood cells Plasma Platelets White blood cells Secondary Components (Blood Derivatives) Created by further processing or fractionating blood components. Some Jehovah’s Witnesses accept these products, depending on individual beliefs and local congregation guidance. Albumin Immunoglobulins Coagulation factor concentrates Cryoprecipitate Autologous vs. Allogeneic Transfusion Allogeneic: from a donor—generally not accepted. Autologous: from the patient’s own circulation—may be accepted if done through a closed-loop system (e.g., cell salvage). This is why personalized planning and transparent communication are essential. Always clarify what the patient will or won’t accept—because individual preferences can vary dramatically within the community. 🛠️ What It Takes to Do Bloodless Medicine Well The best outcomes don’t come from avoiding transfusion—they come from deliberate patient blood management (PBM). Many of the tools that support JW patients improve care systemwide. Preoperative Optimization Iron, B12, and folate supplementation Erythropoiesis-stimulating agents Minimizing iatrogenic blood loss Intraoperative Precision TXA and other antifibrinolytics Meticulous surgical technique Cell salvage (when acceptable) Postoperative Support Tolerance of lower Hgb thresholds Oxygen and volume support Strategies to support marrow recovery 💡 What This Teaches Us Caring for patients who decline transfusion isn’t a constraint—it’s a clinical and ethical opportunity. It pushes us to: Communicate better Plan ahead Treat each patient as a partner in care And above all, it reminds us that the safest blood is the unit we never have to give. 📚 References Jassar AS, Makar M, Pullins E, et al. Cardiac Surgery in Jehovah’s Witness Patients: Ten-Year Experience. Ann Thorac Surg.  2012;93(1):19–25. doi:10.1016/j.athoracsur.2011.07.076 Gemelli M, Italiano EG, Geatti V, et al. Optimizing Safety and Success: The Advantages of Bloodless Cardiac Surgery. A Systematic Review and Meta-Analysis of Outcomes in Jehovah’s Witnesses. Curr Probl Cardiol.  2024;49(1, Part B):102078. doi: 10.1016/j.cpcardiol.2023.102078

I plugged in the numbers—height, weight, sex—and the algorithm spit out a total blood volume of 8 liters. Eight liters. That’s more than the average adult elephant. Okay, not really—but it was definitely more than was physiologically plausible for the patient in front of me. On paper, the formula worked. In practice, it made no sense. And that’s the quiet danger of laboratory standardization: the illusion of precision without the reality of accuracy. Algorithms, equations, and scoring systems are everywhere in lab medicine. We use them to estimate total blood volume, calculate corrected count increments, determine transfusion thresholds, risk-stratify patients, and more. They are essential. They are powerful. And they are, too often, blindly applied. Because we’ve come to equate “standardized” with “valid,” even when the standard was built on shaky ground. The Allure—and Illusion—of the Standard Standardization is the bedrock of laboratory medicine. It’s what lets us compare results across institutions, apply clinical guidelines, and run multicenter trials. Without it, evidence-based medicine would fall apart. But standardization is only as good as the data and assumptions it rests on. And in lab medicine, those assumptions are rarely neutral. When you dig into where these formulas come from—whether it’s Nadler’s formula for TBV, the use of sex-specific reference ranges, or scoring systems for conditions like heparin-induced thrombocytopenia or DIC—you often find something surprising: a very narrow foundation. Many of these tools were derived from datasets that are small, homogeneous, and unrepresentative of the patients we see today. And once a tool is canonized—once it makes it into the LIS, into the protocol, into the reference manual—it becomes difficult to question. But we should. Where Bias Hides in Plain Sight Bias in lab medicine isn’t always dramatic. Sometimes, it’s a small nudge—enough to make a test look slightly more normal than it should, or an algorithm overshoot the mark. But when scaled across thousands of patients, those nudges matter. 🧮 Biased Formulas Take total blood volume. Nadler’s formula is widely used and appears straightforward: plug in height, weight, and sex, and out comes a number. But Nadler’s equation was derived from a limited sample of healthy individuals in the 1960s—primarily white, young, and lean. Apply that formula to a patient with obesity or fluid retention, and you may end up drastically misestimating their TBV. That misestimation can lead to inappropriate collection during apheresis procedures. 📉 Reference Intervals We treat reference intervals as facts, but they’re often closer to educated guesses—highly dependent on the population used to derive them. Hemoglobin and creatinine reference ranges, for instance, are typically stratified by sex assigned at birth, but this binary stratification fails to reflect the diversity of physiologic reality. Patients on hormone therapy, those with chronic conditions, or those with differing muscle mass may fall outside “normal” ranges while being perfectly healthy—or may be misclassified because the ranges were never built with them in mind. Even more problematic, many intervals were never validated in pediatric, geriatric, or racially diverse populations. And yet these ranges shape everything: decisions to transfuse, to screen further, to diagnose. The reference range becomes the gatekeeper to clinical action—even when it shouldn't be. 📊 Risk Scores Scoring systems like the 4Ts for HIT or the ISTH DIC score assume access to certain labs, follow certain clinical patterns, and reward conformity. They can underperform in patients with atypical presentations or resource-limited settings. 🤖 Machine Learning and AI Even newer tools aren’t immune. Predictive models built from EHR data can reflect and amplify existing disparities—especially if the training data skews toward certain populations or omits key variables like socioeconomic status, language access, or prior healthcare usage. Bias doesn’t just live in the past—it gets encoded into the future. The Cost of “Close Enough” We love numbers in the lab. But “close enough” doesn’t cut it when you’re estimating blood volume for a patient with reduced muscle volume, or when a scoring tool steers you away from a diagnosis you should  be considering. Small inaccuracies in algorithms can lead to real-world consequences: missed diagnoses, under-treatment, over-transfusion, delayed care. And the worst part? These errors often go unrecognized—because the numbers looked clean, the boxes were checked, the equation was “standard.” Toward Better, Fairer Standardization So what do we do? We start by asking better questions: Who was this algorithm validated on? What assumptions does it make? Where does it fail? How does it perform in patients who don’t look like the “standard”? We need laboratory professionals involved not just in implementing tools, but in designing and validating them. We need to stop treating standardization as a destination and start treating it as a continuous process—one that requires transparency, adaptability, and humility. And most of all, we need to resist the seduction of certainty. Algorithms can guide us, but they can’t replace judgment. The Patient Didn't Have 8 Liters That patient didn’t have 8 liters of blood. But the algorithm said they did—and if we hadn’t caught it, we might have used that number to justify unsafe collection volumes. That’s the danger: when standardized tools are treated as facts, patients bear the consequences. Because in the end, the algorithm was wrong. And we knew better.

In lab medicine, we’re often asked to prove our worth with narrow metrics—cost per test, turnaround time, test volume. But these siloed measures rarely reflect the full impact of what we do. Over the past few years, I led two studies focused on a single test: the heparin-induced thrombocytopenia (HIT) antibody assay. Both began as practical projects to improve lab performance. But what they revealed went far beyond reagent costs or staffing efficiencies—they told a story about how laboratory decisions can fundamentally shape patient care. A Cost-Effective Innovation With Big Returns In the first study, published in Archives of Pathology & Laboratory Medicine , my team and I evaluated the cost-effectiveness and return on investment (ROI) of bringing the HIT antibody test in-house using the HemosIL platform. Like many institutions, we had been sending these tests out, with turnaround times of 2–4 days—delays that often led to empiric use of expensive heparin alternatives like argatroban. By implementing the assay on existing equipment, we reduced our average turnaround time to just over an hour. That change significantly cut down on unnecessary treatment. We found that the in-house test became cost-effective after as few as 8 tests, and at our institution’s volume, yielded an ROI of up to 298% annually. Fewer Days in the Hospital—But Only When the Test Is Negative The second study, published in American Journal of Clinical Pathology , took things further: Could this lab change improve measurable clinical outcomes? We focused on one critical metric—hospital length of stay (LOS)—and found that patients who had a negative HIT antibody result via in-house testing stayed 3.97 fewer days in the hospital, on average, compared to those with send-out testing. This wasn’t a systemwide trend. There was no decrease in acuity of the patients receiving the test or LOS for the institution as a whole. The reduction was specific to patients with negative test results—those who were able to safely avoid prolonged empiric treatment and be discharged sooner. It’s a clear example of how rapid, high-quality lab data can directly affect clinical decision-making and resource utilization. Moving Past Cost-Per-Test These projects changed how I think about lab value. The traditional cost-per-test model captures only a sliver of the story. It misses what really matters: avoiding harm, reducing overtreatment, shortening stays, saving money systemwide. These are outcomes that matter deeply to patients—and to healthcare systems under strain. To capture that value, we have to stop viewing labs as isolated cost centers and start recognizing them as engines of clinical efficiency. That means bringing lab leaders to the table in decisions about operations, informatics, and patient flow. It means designing metrics that reflect our role not just in diagnosis, but in care. A Path Forward I hope these studies offer a blueprint for others—not just for bringing HIT testing in-house, but for rethinking how we evaluate the success of laboratory innovations altogether. Because when we measure lab value only in terms of cost per test, we ignore everything that happens after the result is released. We ignore the treatment that’s avoided. The hospital days that are saved. The patient who gets discharged sooner, or doesn’t receive an unnecessary drug. We ignore the confidence we give clinicians to make the right call—and the cascading impact that confidence has across an entire health care system. Laboratory medicine isn’t just a line item on a budget. It’s an invisible backbone that supports nearly every clinical decision made in modern medicine. When we optimize the lab—not just for throughput, but for clinical integration—we create meaningful improvements in patient care, safety, and efficiency. That’s value. Not in theory, but in outcomes. It’s time we start telling that story—loudly, clearly, and with data to back it up. Raymond C, Dell’Osso L, Golding C, Zahner C. Cost-Effectiveness and Return on Investment Analysis of an In-house HemosIL Heparin-Induced Thrombocytopenia Antibody Assay at a Mid-Sized Institution.Archives of Pathology & Laboratory Medicine.  Published online 2023.📄 https://doi.org/10.5858/arpa.2023-0141-OA Raymond C, O’Rourke M, Dell’Osso L, Golding C, Zahner C. Analysis of Hospital Length of Stay and Cost Savings With an In-House Heparin-Induced Thrombocytopenia Antibody Assay at a Midsized Institution.American Journal of Clinical Pathology.  Published online 2023.📄 https://doi.org/10.1093/ajcp/aqad152

Pregnancy is a physiological feat—but when complications arise, the blood bank becomes a lifeline. Managing peripartum complications requires careful coordination between the clinical and transfusion teams. In this post, I’ll summarize the critical role of the blood bank in managing pregnancy-related complications, drawing from a recent presentation on this topic. 1. The Pregnant Patient’s Unique Physiology Pregnancy is characterized by profound hematologic and circulatory changes: Total blood volume increases by about 40%, but plasma volume increases by ~50%, leading to a dilutional (physiologic) anemia. Uterine blood flow increases from ~100 mL/min (non-pregnant) to ~700 mL/min at term. These changes optimize fetal perfusion—but they also create the potential for catastrophic hemorrhage. Any peripartum bleeding event occurs against the backdrop of this expanded yet vulnerable intravascular space. 2. Thrombocytopenia and Microangiopathy in Pregnancy: Distinguishing the Causes Pregnancy introduces unique diagnostic challenges when a patient presents with thrombocytopenia, hemolysis, and microangiopathic findings. While true thrombotic microangiopathies (TMAs) such as TTP and aHUS are rare, more common conditions like preeclampsia, HELLP syndrome, and acute fatty liver of pregnancy (AFLP) can present with overlapping laboratory abnormalities. Hypertensive Disorders of Pregnancy: Placental Dysfunction, Preeclampsia, and HELLP The pathophysiology of preeclampsia begins with abnormal placental development. Impaired trophoblastic invasion leads to defective remodeling of spiral arteries, resulting in placental ischemia. In response, the placenta releases antiangiogenic factors (like soluble fms-like tyrosine kinase-1, sFlt-1) into maternal circulation, triggering widespread endothelial dysfunction. This cascade manifests clinically as hypertension and end-organ injury—the hallmark of preeclampsia. While preeclampsia itself is not a thrombotic microangiopathy, the endothelial injury can cause thrombocytopenia, microangiopathic hemolysis, and elevated liver enzymes, mimicking features of TMA. HELLP syndrome represents a severe variant of preeclampsia, defined by hemolysis, elevated liver enzymes, and low platelets. Though it shares some features of TMA, its pathogenesis is rooted in placental dysfunction rather than primary thrombotic microvascular disease. Management of HELLP includes: Delivery of fetus and placenta (definitive treatment) Platelet thresholds: Vaginal delivery: ≥20,000/µL Cesarean delivery: ≥50,000/µL Hemoglobin target: >7 g/dL Coagulopathy: FFP support as needed Most cases of HELLP syndrome resolve within 72 hours postpartum following delivery of the fetus and placenta, which removes the underlying source of endothelial injury and inflammatory mediators. When ongoing thrombocytopenia, hemolysis, or organ dysfunction continues despite delivery and supportive care, therapeutic plasma exchange (TPE) may be initiated as a salvage therapy. While TPE is not routine first-line treatment for HELLP, emerging case series and observational studies suggest it may shorten disease course and reduce morbidity in refractory HELLP, particularly when initiated within 24 hours of delivery. TPE in this context is thought to remove circulating antiangiogenic factors (like soluble fms-like tyrosine kinase-1, sFlt-1) and other inflammatory mediators contributing to endothelial dysfunction. Additionally, it provides plasma replacement, which may help correct associated coagulopathies. Clinicians should have a low threshold for transfusion medicine consultation when HELLP does not follow the expected course of recovery, and the decision to initiate TPE should be individualized based on severity, lab trends, and potential overlap syndromes. True Thrombotic Microangiopathies: TTP and aHUS In contrast, thrombotic thrombocytopenic purpura (TTP) and atypical hemolytic uremic syndrome (aHUS) are true TMAs caused by ADAMTS13 deficiency and complement dysregulation, respectively. They require specific therapies (plasma exchange for TTP; complement inhibition for aHUS). Key differentiating features: Feature HELLP TTP aHUS Timing Late pregnancy/postpartum Any trimester/postpartum Any trimester/postpartum ADAMTS13 activity Normal/mildly low Severely low (<10%) Normal Creatinine Mild elevation Normal/slightly elevated Markedly elevated Platelets Low Very low Low Hemolysis Present Present Present Acute Fatty Liver of Pregnancy: The Great Mimicker AFLP is another critical diagnosis in the differential. Its pathophysiology involves hepatocellular microvesicular steatosis and apoptosis, leading to impaired hepatic function. While AFLP can mimic TMA with thrombocytopenia and coagulopathy, hemolysis is not a defining feature and is often absent. Key distinguishing findings favoring AFLP include: Profound hypoglycemia Elevated ammonia Prolonged PT/INR Low fibrinogen Hepatic encephalopathy Management of AFLP centers on prompt delivery and aggressive correction of coagulopathy with plasma, cryoprecipitate, and platelets to prevent bleeding. 3. Managing Massive Obstetric Hemorrhage: Obstetric MTP Obstetric hemorrhage is the leading cause of maternal mortality worldwide. Unlike trauma, obstetric massive transfusion protocols (MTP) must account for pregnancy-specific hemostatic challenges and the unique pathophysiology of peripartum bleeding. Common inciting events for obstetric MTP include: ✅ Placenta previa ✅ Placental abruption ✅ Uterine rupture ✅ Placenta accreta spectrum (accreta, increta, percreta) Management considerations: Recommended ratio: 1:1.5:1 (RBC:FFP:platelets) Early cryoprecipitate: Hypofibrinogenemia is common and correlates with poor outcomes; administer cryo in the first round if fibrinogen <200 mg/dL. Tranexamic acid (TXA): First-line therapy for postpartum hemorrhage per WOMAN trial. Antibody monitoring: While pregnant patients are not inherently at higher risk of alloantibody formation, any newly formed red cell antibodies following obstetric MTP pose a risk for hemolytic disease of the fetus and newborn (HDFN) in subsequent pregnancies. Therefore, meticulous post-transfusion follow-up with repeat antibody screening is critical to identify alloimmunization. 4. In Pregnancy, All Roads Lead to DIC A central truth of obstetric medicine is that almost every severe complication of pregnancy can induce disseminated intravascular coagulation (DIC). From preeclampsia to placental abruption, AFLP to sepsis, DIC is a common pathway of maternal decompensation. One of the most dramatic examples is amniotic fluid embolism (AFE). Amniotic Fluid Embolism: A Rare but Catastrophic Event AFE is a sudden, unpredictable complication resulting from entry of amniotic fluid into maternal circulation, triggering an anaphylactoid reaction. Risk factors include: ✅ Advanced maternal age ✅ Multiparity ✅ Rapid labor ✅ Cesarean delivery ✅ Instrumental delivery ✅ Placenta previa or accreta Clinically, AFE presents with acute hypoxia, hypotension, cardiovascular collapse, and DIC. Maternal mortality remains high despite optimal supportive care. Blood bank support during AFE focuses on: ✅ Massive transfusion with RBCs, FFP, platelets, and cryoprecipitate to correct consumptive coagulopathy ✅ Maintaining platelets ≥50,000/µL (cesarean) or ≥20,000/µL (vaginal) ✅ Rapid fibrinogen replacement to target fibrinogen >200 mg/dL ✅ Anticipating ongoing bleeding despite lab correction Key Takeaways for the Blood Bank Team ✅ Anticipate hemorrhagic risk in patients with placenta accreta spectrum, previa, abruption, or uterine rupture ✅ Tailor MTP for obstetrics: early cryoprecipitate and TXA are critical ✅ Differentiate causes of thrombocytopenia: preeclampsia/HELLP vs. TTP vs. aHUS dictates treatment ✅ Monitor for DIC in any critically ill pregnant patient ✅ Provide close antibody monitoring: alloantibodies may impact future pregnancies via HDFN even if not problematic in the index pregnancy Pregnancy is a state of delicate balance—and when that balance is lost, the blood bank’s interventions can mean the difference between life and death. Have you encountered these challenges in your practice? Share your experiences and insights below!

When we talk about blood transfusions, most people picture adults — trauma victims, surgical patients, the critically ill. But what about the smallest, most vulnerable patients: children and newborns? Pediatric and neonatal transfusion medicine is a field riddled with tough questions, thin evidence, and sometimes, uncomfortable extrapolations from adult data. Despite heroic efforts by clinicians and researchers, there remains a striking lack of robust, large-scale evidence to guide transfusion decisions in these populations. Why? Because no one wants to experiment on fragile babies. But without strong data, we’re often left making decisions in the dark. In this post, I’m summarizing two comprehensive reviews of current transfusion practices — one focused on pediatric patients 1 and one on neonates 2 — highlighting key studies, existing guidelines, and open questions in the field. These reviews help illuminate both where we’ve made progress and where major evidence gaps remain. Let’s break down what we know, where we’re guessing, and what the latest research is telling us. Pediatric Patients: Blood, Platelets, and Plasma For pediatric red blood cell (RBC) transfusions, guidelines like those from the AABB and TAXI (Pediatric Critical Care and Anemia Expertise Initiative) 3  recommend a restrictive approach — usually transfusing when hemoglobin drops below 7 g/dL in stable, non-cardiac intensive care patients. This approach stems largely from the TRIPICU study, 4  which showed no difference in outcomes (like mortality, infections, or multi-organ failure) between children transfused at 7 g/dL versus 9.5 g/dL. In fact, multiple analyses now suggest no clear benefit to “liberal” transfusion strategies. When it comes to pediatric platelets, things get trickier. Adult guidelines offer thresholds (e.g., 10,000/μL for prophylaxis, 50,000/μL for most surgeries), but evidence in children is sparse — and what we do have suggests that platelet count alone is a poor predictor of bleeding risk. The PLADO trial 5  found that lower platelet doses worked just as well to prevent bleeding, but importantly, children were at higher bleeding risk than adults, regardless of pre-transfusion count. This raises provocative questions: Do kids’ platelets behave differently? Do their vascular systems react in ways we don’t fully understand? For plasma transfusions, the story is sobering. Many plasma transfusions in both children and adults are given to “correct” lab abnormalities (like a high INR) before procedures when no bleeding is present — but randomized trials consistently show no benefit in such situations. It’s a potent reminder: abnormal numbers don’t always mean intervention is needed. Neonatal Patients: A World Apart Newborns, especially preemies, bring their own unique challenges. Neonatal red cell transfusion practices are influenced by the fascinating physiology of perinatal hematopoiesis. Term infants start with high hemoglobin levels (16–17 g/dL), but experience a “physiologic anemia” around 8 weeks as levels naturally drop before rising again. Premature infants, however, face even steeper drops due to shorter red cell lifespans and immature erythropoiesis. Two recent landmark trials, ETTNO 6  and TOP 7 , compared liberal and restrictive hematocrit thresholds for RBC transfusions in premature neonates. Both found no difference in survival or neurodevelopmental outcomes, supporting a move toward more restrictive strategies — though the nuances (like how early or prolonged anemia affects development) are still being debated. Platelet transfusion in neonates is another evolving area. Thrombocytopenia is common in preemies, but high thresholds (like 50,000/μL) may actually increase the risk of death and bleeding, as shown in the PlaNet-2 study. 8  A lower threshold of 25,000/μL appears safer, especially in the most fragile babies. In neonates, plasma transfusions are typically used for active bleeding, disseminated intravascular coagulation (DIC), severe liver disease, or as replacement fluid during procedures like ECMO or plasma exchange. While abnormal lab values (like elevated INR or aPTT) often trigger plasma use, studies show little benefit in correcting mild or moderate abnormalities in non-bleeding infants. This is partly because neonatal coagulation is naturally different: most clotting factors are around 50% of adult levels, but factors like fibrinogen, Factor V, Factor XIII, Factor VIII, and vWF are at or above adult levels at birth. Cryoprecipitate is mainly used to replace fibrinogen in cases of hypofibrinogenemia or dysfibrinogenemia, especially when bleeding or before surgery. Some centers are exploring human fibrinogen concentrate as an alternative, but thresholds for when to treat (often <100–150 mg/dL) remain debated. Importantly, routine prophylactic use of plasma or cryo in non-bleeding neonates is not well supported by evidence. What’s Next? If there’s a unifying theme across pediatric and neonatal transfusion medicine, it’s this: We need more and better evidence, and we need to stop reflexively applying adult rules to tiny bodies. Future research must tackle not just laboratory thresholds, but meaningful clinical outcomes — survival, development, quality of life. We also need smarter tools to assess bleeding risk beyond raw platelet counts or clotting times, especially in neonates whose physiology is fundamentally different. Until then, clinicians must walk a delicate line: applying the best available evidence, challenging outdated practices, and recognizing when “normalizing the numbers” may do more harm than good. Final Thoughts Pediatric and neonatal transfusion medicine asks us to confront some of the hardest questions in healthcare: How do we protect our most vulnerable patients without overreacting to imperfect data? How do we balance caution with evidence? And how do we, as stewards of limited and precious blood products, make sure we’re giving — or holding back — for the right reasons? In the end, perhaps the most powerful transfusion decision is the one not made lightly. Mo YD, Delaney M. Transfusion in Pediatric Patients. Clin Lab Med . 2021;41(1):1-14. doi:10.1016/j.cll.2020.10.001 Zerra PE, Josephson CD. Transfusion in Neonatal Patients. Clin Lab Med . 2021;41(1):15-34. doi:10.1016/j.cll.2020.10.002 Valentine SL, Bembea MM, Muszynski JA, et al. Consensus Recommendations for RBC Transfusion Practice in Critically Ill Children From the Pediatric Critical Care Transfusion and Anemia Expertise Initiative. Pediatric Critical Care Medicine . 2018;19(9):884-898. doi:10.1097/PCC.0000000000001613 Lacroix J, Hébert PC, Hutchison JS, et al. Transfusion Strategies for Patients in Pediatric Intensive Care Units. New England Journal of Medicine . 2007;356(16):1609-1619. doi:10.1056/NEJMoa066240 Slichter SJ, Kaufman RM, Assmann SF, et al. Dose of Prophylactic Platelet Transfusions and Prevention of Hemorrhage. New England Journal of Medicine . 2010;362(7):600-613. doi:10.1056/NEJMoa0904084 Franz AR, Engel C, Bassler D, et al. Effects of Liberal vs Restrictive Transfusion Thresholds on Survival and Neurocognitive Outcomes in Extremely Low-Birth-Weight Infants. JAMA . 2020;324(6):560. doi:10.1001/jama.2020.10690 Kirpalani H, Bell EF, Hintz SR, et al. Higher or Lower Hemoglobin Transfusion Thresholds for Preterm Infants. New England Journal of Medicine . 2020;383(27):2639-2651. doi:10.1056/NEJMoa2020248 Curley A, Stanworth SJ, Willoughby K, et al. Randomized Trial of Platelet-Transfusion Thresholds in Neonates. New England Journal of Medicine . 2019;380(3):242-251. doi:10.1056/NEJMoa1807320

At 2AM, the hospital feels like a different world. The corridors are dim and quiet. Most of the offices are dark. The cafeteria is probably closed. But in the blood bank, the phones still ring. Orders still come in. Patients still need care. And stewardship—the quiet, deliberate act of balancing urgency with responsibility—becomes more critical than ever. When most of the world is asleep, someone still has to make the hard decisions. Stewardship in the Dark In healthcare, stewardship often gets defined in big, formal ways: committees, policies, utilization reviews. But at 2AM, stewardship isn’t a meeting. It’s not a spreadsheet. It’s a person, standing at the crossroads of limited information and immediate need, trying to do the most good with what they have. It’s a blood bank technologist deciding whether to release the last two units of O-negative blood to an unstable trauma patient—or to hold one back in case another trauma rolls through the door. It ’s a pathologist on call weighing whether to approve thawed plasma for a patient who might need it—or might not—knowing that once thawed, the product will expire in just five days. It ’s a team trying to explain, with grace and speed, why "not yet" or "not that product" might be the safest answer. At 2AM, stewardship is a human act, made under pressure, with no second chances. The 2AM Reality: Decisions Without a Net Stewardship at 2AM often means: 🔹 Inventory is thin. The platelet shelf is almost empty. The freezer is down to the last few units of AB plasma. O-negative red cells—always precious—are running low. 🔹 The phone still rings. A massive transfusion protocol is activated for a multi-vehicle crash. The NICU needs a rare antigen-negative unit—immediately. A cancer patient in the ICU is bleeding and thrombocytopenic, and the crossmatch is tricky. 🔹 There’s no luxury of perfect information. Lab values may be outdated. Clinical details may be incomplete. Sometimes you’re relying on a panicked voice on the phone—and your training, your protocols, and your gut. This is stewardship under fire. Not the clean, theoretical kind. The raw, real-world version, when judgment must fill in the blanks. The Emotional Weight of Stewardship The work of stewardship isn’t just technical. It’s emotional. 🔹 Fatigue: making high-stakes decisions when your body aches for sleep. 🔹 Isolation: often, there’s only one tech, one blood banker, and one pathologist covering the whole system. 🔹 Responsibility: knowing that if you make the wrong call—if you release the wrong unit, or delay too long—patients could suffer. Every decision echoes beyond the moment. The trauma patient stabilized at 2:30AM may survive because the blood bank stretched the supply just far enough. The pediatric patient at 5AM may receive a rare unit because someone had the courage to hold back earlier in the night. Stewardship isn’t always about saying "no." Sometimes it’s about saying "yes" carefully, wisely, bravely. A Story from the Night Shift I remember one night when we were down to just a handful of O-negative red cells. A trauma team called—young female patient, unstable, hypotensive. They wanted a cooler packed, ready to go. We sent two units immediately. Held some back. It was a hard call. The ER team wanted more. I understood why. But minutes later, another call came in—a pregnant patient, massive hemorrhage, historical blood type O-negative. Those last units saved a second life. It wasn’t heroism. It was stewardship. Quiet, uncelebrated, but essential. What Stewardship Teaches Us Stewardship teaches us that medicine is not about hoarding resources—or about reckless generosity. It’s about discernment. About prioritizing with compassion. About doing the best we can for every patient, seen and unseen. At 2AM, stewardship doesn’t feel glamorous. It feels exhausting. Lonely. Sometimes even invisible. But it defines the best of who we are in laboratory medicine. Stewardship is advocacy. Stewardship is courage. Stewardship saves lives we’ll never even know. Conclusion At 2AM, when no one is watching, stewardship happens. One decision. One unit. One patient at a time. Not with applause. Not with headlines. But with quiet excellence—the kind that holds the whole system together. And that is what stewardship really looks like.

To the ones who didn’t match — this one’s for you. I. The Experience of Not Matching You logged in. Your heart raced. And then came the words — or the silence — that knocked the wind from your lungs. You didn’t match. Let’s name it for what it is: devastating. Not matching can feel like a gut punch to your confidence, your sense of self-worth, your entire timeline. It’s not just professional rejection — it can feel like personal failure. In the days and weeks that follow, that weight can settle heavily. You may question every choice you made to get here. You may withdraw, keep it quiet, feel ashamed. Depression is a real risk in this space. If you're in that place, please know: you are not alone. Seek help. Talk to someone — a mentor, a friend, a therapist. You are still a doctor. You are still worthy. And this is not the end of your story. II. The Reality of Not Matching Let’s be honest — this wasn’t what you planned. There are real losses: a job you hoped for, a path you dreamed of, a life you were ready to begin. There's real uncertainty: about the scramble, the SOAP, the year ahead, the next steps. But here’s the strange twist — you've just been given something few physicians ever get. Time. An entire open year, plucked from the chaos of training. A gap in the relentless progression. What will you do with it? This isn’t a detour — it’s a chance to choose your path, not just follow the map. III. The Open Opportunities When You Don’t Match The year ahead is not a void — it’s a canvas. You can seek observerships, shadow physicians in specialties you never had time to explore. You can volunteer, embedding yourself in community work that reminds you why you chose medicine in the first place. You can do research — clinical, bench, or something totally different. You can dive into public health or policy or medical education. You can try on a new lens: explore a specialty you never considered, lend your time to grassroots organizations, or bring science into spaces that don’t usually see it. And if this year broke your heart? You are allowed to rest. You are allowed to grieve. Travel if you can. Paint, write, walk, be. You are allowed to be a person first — not just a resume. That, too, will make you a better doctor. IV. Facing the Stigma Yes, the stigma exists. You may encounter awkward questions or raised eyebrows. But it will not be as pervasive as you fear. And it will not define you. You’ll be surprised at how many giants in medicine didn’t match the first time. They don’t always talk about it — but maybe you will. Maybe you’ll help change the culture. Because medicine needs people who understand failure. We need doctors who know that failure is not a moral judgment. It’s a moment in a whole complex life. It’s part of being human. You will grow from this. You will learn more than you ever wanted to. And it will make you wiser, kinder, and more resilient. V. Life Will Go Sideways This might be the first big derailment. It won’t be the last. Life doesn’t run on rails, and medicine doesn’t either. Illness happens. Grief happens. Mistakes, unexpected changes, systems that fail you — they all come. But this is not your fault. You are still worthy. This is hard. But you can do hard things. You already have. VI. Taking the Long Road The long road winds. It’s not always smooth. There will be potholes, cliffs, and wrong turns. But there are also breathtaking views. This path will bring you insight — into yourself, into the system, into your patients. It will enrich your empathy. It will shape your compassion. You are not behind. You are just on the scenic route. Take a deep breath. Look around. This long road? It’s yours now. And it just might take you somewhere beautiful.

At 3 a.m., the laboratory is quiet—but not still. Centrifuges hum. Blood cultures incubate. Analyzers click methodically. On the clinical floors, most people never see this world. They see results—platelet counts, blood types, positive cultures—neatly logged in the chart. What they don't see is the invisible emotional labor carried by laboratory professionals behind every number. In medicine, we talk about compassion, vigilance, and resilience. But we often forget that these qualities live in the lab too—silently, without ceremony, without acknowledgment. And they matter just as much. The Work You Never See The emotional labor of lab medicine comes in many forms. Some of it looks like science. Most of it feels like vigilance, responsibility, and fear carefully tucked beneath professionalism. 🔹 Catching errors before they happen. A mislabeled specimen, a critical value that doesn’t fit the clinical picture, a blood type discrepancy. Every day, lab professionals spot small inconsistencies that could become disasters if left unchecked. They make the extra call, rerun the sample, refuse to release a unit that doesn't feel right. No one thanks them for the mistake that didn’t  reach the patient. But the patient lives because of it. 🔹 Making high-stakes decisions with limited information. A trauma team needs uncrossmatched blood now. An oncology patient is deteriorating and desperately needs platelets, but inventory is razor-thin. The blood bank has to weigh risks, make judgment calls, and release products in imperfect conditions—knowing the consequences could be profound. There isn’t always time for certainty. Just decision, action, responsibility. 🔹 Carrying the weight of the “what-ifs.” What if I had missed that critical potassium? What if that platelet transfusion delay harmed the patient? What if my best wasn’t enough? In the lab, victories are invisible. Near-misses haunt quietly. We measure ourselves not by the work seen, but by the disasters averted without fanfare. 🔹 Shouldering grief without formal closure. When a patient dies, the clinical teams mourn at the bedside. In the lab, sometimes all we get is the silence of a canceled order. We don’t know the patient’s name. We don’t meet their family. But we carry the ache anyway—the knowledge that we tried, and sometimes, it wasn’t enough. Why This Labor Is Invisible Part of it is geography—the lab is physically separate, often tucked in the basement or a distant wing. Part of it is culture—laboratory work is expected to be perfect, precise, anonymous. When we succeed, the system moves forward seamlessly. When we fail, it’s catastrophic. Healthcare tends to reward visible labor: the surgery completed, the code called, the wound closed. But the preventive work—the countless small interventions that make disaster impossible—is just as vital. In lab medicine, success is quiet. That doesn’t make it any less heroic. Honoring the Hidden Work It’s time we acknowledge the emotional labor of laboratory medicine—and care for the people who carry it. Build space for debriefs after critical events. Foster psychological safety so errors can be discussed without shame. Recognize laboratory contributions in clinical successes—not just when things go wrong. The lab is not just a factory for numbers. It’s a sanctuary of vigilance. And the people who work there deserve to have their emotional labor seen, honored, and supported. Conclusion Every second glance at a specimen. Every extra phone call. Every choice to pause, question, double-check. These quiet acts save lives. Even when no one sees them. Especially when no one sees them.

It usually starts with a phone call. A stat request for platelets. A patient with a dropping hemoglobin. A unit needed now —no crossmatch, no time. On the other end of the line, urgency crackles. A resident, an intensivist, a trauma team nurse—someone advocating fiercely for their patient. And then there’s the blood bank. Pausing. Weighing. Sometimes, saying “no.” To the uninitiated, that “no” may seem callous. Bureaucratic. But in truth, it is one of the most difficult decisions we make—and one of the most ethical. The Hidden Cost of Always Saying “Yes” Blood is not infinite. Not in quantity, not in compatibility, and not in clinical value. Platelets expire after five days. AB plasma is rare. Irradiated units must be reserved for vulnerable patients. O negative red cells are gold. Each decision to transfuse is a commitment: to the patient in front of you, yes—but also to every other patient who may need that unit later today, or tomorrow. In transfusion medicine, we live in the space between individual urgency and collective responsibility. That’s why the blood bank sometimes has to say “no.” Not because we don’t care. But because we care about everyone. Behind Every ‘No’ Is a Deliberate Process These decisions aren’t made in isolation. They’re shaped by guidelines, clinical indications, inventory levels, and patient context. We review lab values and diagnoses, weigh transfusion thresholds, and, when necessary, discuss alternative strategies. We call the team back. We offer alternatives—what about tranexamic acid? Can we recheck that hemoglobin? Is the patient bleeding or just anemic? Often, the “no” is really a “not now” or “not this product.” Every decision is collaborative. Thoughtful. Anchored in evidence. And yes—human. Teaching Moments in Tense Moments When a transfusion request is denied, it can trigger frustration. After all, the clinical team is advocating for their patient. But in those moments, there’s an opportunity—for education, for dialogue, for building mutual understanding. We’re not here to police decisions. We’re here to support them. That means teaching when transfusions help—and when they don’t. It means empowering residents to consider thresholds, risks, and alternatives. And it means listening, always, to the real-world pressures on the wards. Because we’ve been there too. Holding the Line with Compassion It’s easy to say yes. It feels good. But sometimes, saying no is the harder, better thing. We say no because we are stewards—not just of inventory, but of evidence. We say no because we’ve seen transfusions help and harm. And we say no because we understand what’s at stake—on both ends of the phone. So the next time the blood bank hesitates, know this: we’re not just looking at lab values or inventory charts. We’re thinking about your patient. And someone else’s patient. And the ones we haven’t met yet. Saying no is never easy. But sometimes, it’s the most caring thing we can do.

A letter about love, science, and the quiet power of staying human. Dear student, If you are thinking about medicine right now—while the world feels like it’s unraveling, while systems you once trusted buckle under weight they can no longer carry—I want you to know: I see you. Maybe you're weighing your options, staring down the long road of training and debt, and wondering if this is the right time to give yourself to something so demanding. Maybe you're watching your friends go into business or tech, finding faster paths to comfort, stability, solvency. Maybe you're asking yourself the quiet, painful question: Is this worth it anymore? And I want to tell you: I’ve asked that question, too. There are plenty of reasons to walk away. The costs are real—financial, emotional, existential. The debt piles up. The hours bleed into each other. You will miss weddings, and birthdays, and sometimes pieces of yourself. You will see suffering that no textbook could prepare you for, and you’ll wonder if you're strong enough to bear it. Some days, you won’t be. The system is imperfect. The pressures are relentless. And the public, at times, forgets that beneath the white coat is a human heart that also aches. But. There is something else. There is the moment you hold someone’s lab result in your hands and realize you are holding the beginning of an answer. There are the times you explain a diagnosis, and a patient’s fear gives way to understanding. There is the quiet, ordinary miracle of watching a transfusion bring color back into someone’s face. There is the intimacy of bearing witness to a life at its most vulnerable—and being allowed to help. Medicine is not just a profession. It is a form of service. Of listening. Of relentless curiosity. Of saying, Even when it’s hard, I will stay. Science, at its best, is an act of hope. It insists that even in the chaos, there is order to be found. That questions are worth asking. That the body can be understood—and that understanding can heal. This work will not make you rich. It will not make you famous. You won’t IPO a transfusion. You won’t go viral for stabilizing someone’s electrolytes. But you will matter. Your presence will matter. And that is why, while the world burns, this work still calls. Not because it is easy. But because it is human . Because someone has to hold the line. Someone has to kneel beside the broken systems and still choose to do the next right thing. You could walk away. You would not be weak if you did. But if you stay—if you choose this—then I hope you know: you are not alone. You walk in the footsteps of people who believed that service is sacred. Who stitched science and compassion into something like a life’s purpose. Who knew that dignity is not a line on a resume—it is how you show up, over and over, even when no one is watching. So if you are still wondering: Yes, this path is hard. Yes, it is flawed. Yes, the world is burning. But there is still healing to be done. And medicine—this stubborn, beautiful, aching thing—is still worth loving. Still worth doing. Still worth you. With all my heart, Caitlin Raymond, M.D., Ph.D.